Skip to main content
SpringerLink
Log in

Miscellaneous Agents

  • Chapter
  • First Online:
Drug Dosing in Obesity

  • 847 Accesses

Abstract

Dosing recommendations for a number of antimicrobial classes are presented in the previous chapters. A number of antimicrobials have very little information on the pharmacokinetics (PK) variability or dosing strategies for obese patients. This chapter will briefly outline the literature and dosing recommendations for other miscellaneous antimicrobials that are not presented elsewhere in this book. Dosing recommendations for these agents in obese patients have been made based on the limited available information. There is an urgent need for robust PK studies of many antibiotics that are commonly used in obese patients to guide dosing recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Australian Medicines Handbook 2015 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2015. Available from: http://amhonline.amh.net.au/.

  2. Micromedex® 2.0 (electronic version). Truven health analytics, Colorado, USA. Available from: http://www.micromedexsolutions.com.acs.hcn.com.au/. Registration and login required.

  3. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. DynaMed Plus [Internet]. Ipswich (MA): EBSCO information services; 1995. Available from http://www.dynamed.com. Registration and login required.

  5. Therapeutic Goods Administration. Colistin PI. [Internet]: Australian Government Department of Health; 2015 [updated 12 Aug 2015; cited 2015]. Available from: www.ebs.tga.gov.au.

  6. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother. 2012.

    Google Scholar 

  7. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis. 2013;56(3):398–404.

    Article  CAS  PubMed  Google Scholar 

  8. Yilmaz GR, Bastug AT, But A, Yildiz S, Yetkin MA, Kanyilmaz D, et al. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens. J Infect Chemother. 2013;19(1):57–62.

    Article  CAS  PubMed  Google Scholar 

  9. Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther. 2014;39(3):272–6.

    Google Scholar 

  10. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011;1(30):1–6.

    Google Scholar 

  12. DeRyke A, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jm P, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–84.

    Article  Google Scholar 

  14. Mohameda AF, Karaiskosc I, Plachourasc D, Karvanend M, Pontikise K, Janssona B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241–9.

    Article  Google Scholar 

  15. Spizek J, Novotna J, Rezanka T. Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Adv Appl Microbiol. 2004;56:121–54.

    Article  CAS  PubMed  Google Scholar 

  16. Katzung BG, Masters SB, Trevor AJ, editors. Basic & clinical pharmacology. 12th ed. USA: McGraw-Hill Companies; 2012.

    Google Scholar 

  17. Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol. 2012;74(6):971–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mastrobattista JM, Klebanoff MA, Carey JC, Hauth JC, Macpherson CA, Ernest J, et al. The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy. Am J Perinatol. 2008;25(4):233–7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cerqueira RM, Correia MR, Vilar H, Manso MC. How effective is the quadruple concomitant helicobacter pylori eradication therapy for obese patients undergoing gastric bypass surgery? Obes Surg. 2015.

    Google Scholar 

  20. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36(5):353–73.

    Article  CAS  PubMed  Google Scholar 

  21. Sweetman S, editor. Martindale: the complete drug reference. London: Pharmaceutical Press (Electronic version); 2015.

    Google Scholar 

  22. Hernandez JO, Norstrom J, Wysock G. Acyclovir-induced renal failure in an obese patient. Am J Health-Syst Pharm. 2009;66:1288–91.

    Article  PubMed  Google Scholar 

  23. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther. 2014;39(6):584–608.

    Article  CAS  PubMed  Google Scholar 

  24. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997;25:112–8.

    Article  CAS  PubMed  Google Scholar 

  25. Seedat A, Winnett G. Acyclovir-induced acute renal failure and the importance of an expanding waist line. Brit Med J. 2012.

    Google Scholar 

  26. Therapeutic Goods Administration. Oseltamivir PI. [Internet]: Australian Government Department of Health; 2015 [updated 14 October 2015; cited 2015]. Available from: www.ebs.tga.gov.au.

  27. eTG Complete [Internet]. Therapeutic Guidelines Limited. 2014.

    Google Scholar 

  28. Beck MA. Influenza and obesity: will vaccines and antivirals protect? J Infect Dis. 2012;205:172–3.

    Article  PubMed  Google Scholar 

  29. Huttunen R, Karppelin M, Syrjänen J. Obesity and nosocomial infections. J Hosp Infect. 2013;85:8–16.

    Article  CAS  PubMed  Google Scholar 

  30. Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WRJ, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. 2014;58(3):1615–21.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081–91.

    Article  CAS  PubMed  Google Scholar 

  32. Thorne-Humphrey LM, Goralski KB, Slayter KL, Hatchette TF, Johnston BL, McNeil SA. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011;66:2083–91.

    Article  CAS  PubMed  Google Scholar 

  33. Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis. 2011;52(4):457–65.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Rodríguez A, Díaz E, Martín-Loeches I, Sandiumenge A, Canadell L, Díaz JJ, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother. 2011;1–10.

    Google Scholar 

  35. Longo C, Bartlett G, Macgibbon B, Mayo N, Rosenberg E, Nadeau L, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, Hobart, TAS, 7001, Australia

    Eleanor van Dyk, Rahul P. Patel & Syed Tabish R. Zaidi

Authors
  1. Eleanor van Dyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul P. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed Tabish R. Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Tabish R. Zaidi .

Editor information

Editors and Affiliations

  1. Division of Pharmacy, School of Medicine, University of Tasmania School of Medicine, Hobart, Tasmania, Australia

    Syed Tabish R. Zaidi

  2. School of Medicine and School of Pharmacy, Burns, Trauma and Critical Care Res Cntr, University of Queensland Burns, Trauma and Critical Care Res Cntr, Brisbane, Queensland, Australia

    Jason A. Roberts

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

van Dyk, E., Patel, R.P., Zaidi, S.T.R. (2016). Miscellaneous Agents. In: Zaidi, S., Roberts, J. (eds) Drug Dosing in Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-44034-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44034-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44032-3

  • Online ISBN: 978-3-319-44034-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation